Medical expert committee to review BNT162b2 vaccine
The coronavirus (COVID-19) vaccine created by U.S. pharmaceutical company Pfizer and German drugmaker Bio’N’Tech is set for a final review for emergency use by the FDA. If this vaccine is approved, it could be the first COVID-19 vaccine available in the U.S. and could be available for use within days of approval.
COMING UP: At 9 a.m. today, the Vaccines and Related Biological Products Advisory Committee meeting is scheduled to begin.
The committee will discuss the EUA request for a #COVID19 vaccine from Pfizer/BioNTech.
Watch it live here. pic.twitter.com/xz2AXcBnGE
— U.S. FDA (@US_FDA) December 10, 2020
A 17-member independent Vaccines and Related Biological Products Advisory Committee (VRBPAC) will start reviewing data of the BNT162b2 vaccine this morning with a live-stream of the meetings for the general public. The choice to host a live-stream event of the meeting for a transparent process that involves the general public that will end around 5:15 p.m. with an expected vote from the VRBPAC committee.
Though there will be an opportunity for a vote, this doesn’t necessarily mean the committee will come to a decision immediately but there are indications that BNT162b2 will be approved. On Tuesday, the FDA published an overview of BNT162b2’s effectiveness and safety for use with the vaccine meeting all the criteria required by the FDA.
The BNT162b2 vaccine was approved for emergency use for the UK and has delivered the first round of doses since approval last week. The only set-back of the BNT162b2 vaccine was a couple of adverse allergic reactions.
This is what the UK's Covid-19 vaccination cards will look like. Britain's healthcare providers are preparing to start administering the first doses of the vaccine tomorrow. https://t.co/gpbr9RpLFx
— CNN (@CNN) December 7, 2020
If the VRBPAC recommends authorization, the FDA is expected to approve the vaccine for emergency use as soon as Thursday night for distribution across all 50 states. The data shows evidence of the short-term safety and effectiveness of the BNT162b2 vaccine but the study process was compressed with limited data on how long the vaccine will continue to be effective.
-
Former President Donald Trump Leaves Republicans Speculating on His Debate Strategy Former President Donald Trump has definitively confirmed that...
-
The recent incident involving U.S. soldier Travis King, who crossed from South Korea into North Korea, has garnered significant...
-
The U.S. President assures support and aid as island grapples with Deadly wildfires and recovery challenges US President Joe...
-
Tragedy unfolds as FBI confronts man over alleged threats against President Biden An incident unfolding on Wednesday shocked the...
-
Protecting the Process in Trump’s January 6 Case In the federal courthouse of Washington, DC, security measures surrounding the...
-
A New York Times/Siena College poll reveals surprising results A recent New York Times/Siena College poll reveals an intriguing...
-
Phoenix, Arizona, experienced a record-breaking stretch of scorching temperatures above 110F (43.3C) that finally came to an end yesterday...
-
Ron DeSantis Defends Florida’s New Slavery Curriculum Ron DeSantis, the Governor of Florida, recently defended introducing new education standards...
-
A Heartfelt Farewell to Tafari Campbell Over the weekend, a somber atmosphere enveloped Martha’s Vineyard as news spread about...
-
Caught on Camera: Hunter Biden’s “Sugar Brother” Lawyer in Bong Scandal In a recent incident, Kevin Morris, a prominent...
-
Breaking the Chains: Biden Administration Erases $39 Billion in Student Loan Debt. In a move aimed at providing much-needed...
-
Controversial Claims: Robert F. Kennedy Jr. Faces Backlash Over Covid Conspiracy Theories Robert F. Kennedy Jr.’s recent conspiracy-filled tirade...